SCHEMBL26129358

SCHEMBL26129358

CC(C)C(=O)OCOC(=O)N1CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
THRB P10828 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 2/20 0.39
PRMT5 O14744 2/20 0.38
WDR77 Q9BQA1 2/20 0.38
TSHR P16473 2/20 0.38
HTT P42858 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
RECQL P46063 1/20 0.35
GAA P10253 1/20 0.35
HSD11B1 P28845 1/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
CASP6 P55212 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26131514 0.81 ALDH1A1 (0.42) ALDH1A1HPGDMEN1KMT2ATHRB
SCHEMBL27900748 0.79 ALDH1A1 (0.42) ALDH1A1HPGDMEN1KMT2ATHRB
SCHEMBL11559149 0.79 ALDH1A1 (0.43) ALDH1A1HPGDMEN1KMT2ATHRB
SCHEMBL5512792 0.78 HPGD (0.40) ALDH1A1HPGDMEN1KMT2ATHRB
SCHEMBL24495958 0.77 TPSAB1 (0.45) ALDH1A1THRBATML3MBTL1GAA
SCHEMBL3768429 0.77 KMT2A (0.55) ALDH1A1HPGDMEN1KMT2ATHRB
SCHEMBL23490321 0.76 ALDH1A1 (0.46) ALDH1A1MEN1KMT2ATSHRHTT
SCHEMBL14215515 0.76 HTT (0.41) ALDH1A1HPGDMEN1KMT2ATHRB
SCHEMBL28109077 0.76 TSHR (0.42) ALDH1A1THRBATML3MBTL1POLB
SCHEMBL11402027 0.76 ALDH1A1 (0.61) ALDH1A1THRBATML3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206724-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2025-06-26 US disclosed
EP-4499612-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2025-02-05 EP disclosed
WO-2023186773-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-10-05 WO disclosed
WO-2023186773-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206724-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS CDK1, CDK11A, CDK3 ALDH1A1 4385/4885HPGD 2141/4885MEN1 2577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.